The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
August 19, 2024
Adagrasib (Krazati) for Colorectal Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Adagrasib (Krazati) for Colorectal Cancer (online only)
August 19, 2024 (Issue: 1709)
The RAS GTPase family inhibitor adagrasib (Krazati –
BMS), which received accelerated approval for
treatment of KRAS G12C (glycine-to-cysteine mutation
at codon 12)-mutated locally advanced or metastatic
non-small cell lung cancer (NSCLC) in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.